Developer docs
API playgroundTry for free, no card

Search company profiles

Luye Pharma

Full company profile

uuid003758g

Namestring
Luye Pharma
Legal namestring
绿叶制药集团有限公司 (Luye Pharma Group Co., Ltd.)
Websiteurl
luye.cn
Company typeenum
Public
Founded yearint
1994
Descriptiontext

Luye Pharma Group (HKEX: 02186.HK) is a Hong Kong-listed specialty pharmaceutical company founded in 1994 and headquartered in Yantai, Shandong Province, with secondary operations in Shanghai. A subsidiary of Luye Life Sciences Group, it generates the substantial majority of its roughly RMB 6.3 billion (~$870M USD) FY2025 revenue from innovative and generic drugs across three therapeutic franchises — oncology (Baituowei goserelin microsphere, Zanbijia lurbinectedin), CNS (ERZOFRI paliperidone palmitate in the US, Rykindo risperidone microsphere, Ruoxinin for depression, rivastigmine and rotigotine transdermal patches), and cardiovascular/diabetes/ophthalmology — with an OTC health and wellness tail. Approximately 50 approved products are sold in over 80 countries through self-operated commercial teams in China and the US, supplemented by distribution partnerships with Sinopharm and Enhua Pharma in China and international commercialization partners in Europe, Japan, and Southeast Asia.

Short descriptiontext

Luye Pharma is a Hong Kong-listed specialty pharmaceutical company developing innovative drugs in oncology, CNS, and cardiovascular therapy using proprietary microsphere, liposome, and transdermal delivery platforms, with operations in 80+ countries and manufacturing across 8 global bases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative pharmaceutical drugs, specialty oncology drugs, CNS therapeutics, drug delivery platforms, biologic drug development
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sale of innovative drugs, generic drugs, and over-the-counter (OTC) health and wellness products across three segments: oncology, CNS (central nervous system), and cardiovascular. The company operates across 80+ countries including China, US, Europe, Japan, and emerging markets.

luye.cn
2New Product Commercialization
TypeOne Time License
Description

Revenue growth driven by commercialization of newly launched products including ERZOFRI® (paliperidone palmitate injectable suspension) in US, Rykindo® (risperidone long-acting microspheres), and other innovative drugs in China and global markets. New product revenue grew 56.8% year-over-year in 2025.

luye.cn
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Rykindo (瑞可盈)
Description

Risperidone extended-release microsphere injection - treatment for schizophrenia, launched in US

luye.cn
+5 more records
Core offering1 text field

Luye Pharma is an international pharmaceutical company that researches, develops, manufactures, and commercializes innovative drugs across three core therapeutic areas: oncology, central nervous system (CNS) disorders, and cardiovascular diseases. The company operates advanced drug delivery technology platforms including microspheres, liposomes, and transdermal patches, and has a portfolio of approximately 50 approved products sold across 80+ countries through its 8 global manufacturing bases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • New product revenue grew 56.8% in 2025
+3 more records
Product overview1 text field

Luye Pharma is an international pharmaceutical company dedicated to innovative drug R&D, manufacturing, and sales. The company focuses on three core therapeutic areas: anti-tumor chemotherapy drugs, central nervous system (CNS) innovative drugs, and biologics. Its advanced drug delivery technology platforms include microsphere, liposome, and transdermal delivery systems at international levels. The portfolio includes: CNS drugs such as ERZOFRI® (paliperidone palmitate monthly injection), Rykindo® (risperidone microsphere injection), and 若欣林® (for depression); oncology drugs including 百拓维® (goserelin microsphere) and 赞必佳® (lurbinectedin); biologic products like 博优景® (aflibercept) and 博优平® (dulaglutide); and transdermal patches including 利斯的明透皮贴剂 and 罗替高汀贴剂. The company has achieved 15 new product approvals across the US, China, Japan, and Europe between 2021-2025, with a robust pipeline including LY03015, LY03017, and LY03020 in CNS and various biologic candidates. Luye Pharma operates 8 global manufacturing bases and maintains an international GMP quality management system.

Product and service4 records
1ERZOFRI® (paliperidone palmitate extended-release suspension injection)
CategoryCNS Drug
Description

Monthly injectable for schizophrenia treatment; the only paliperidone palmitate monthly injection in the US offering a 'first month one injection' dosing regimen. Launched in the US in April 2025.

2Rykindo® (risperidone extended-release microsphere injection)
CategoryCNS Drug
Description

Long-acting injectable for schizophrenia treatment using microsphere drug delivery. Approved and launched in the United States.

3若欣林® Ruoxinin (tolafrazine sustained-release tablets)
CategoryCNS Drug
Description

China's first self-developed Class 1 innovative chemical drug for depression treatment. Included in China's national medical insurance with rapid market penetration and received Level 1A recommendation as first-line treatment in the 2025 China Depression Prevention and Treatment Guidelines.

4百拓维® Baituowei (goserelin long-acting microsphere injection)
CategoryOncology Drug
Description

The world's only currently marketed goserelin long-acting microsphere formulation for prostate cancer and breast cancer. Renewed in China's national medical insurance directory at the end of 2025 with multiplicative sales growth.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-01
Description

Strategic collaboration with Sinopharm Group and Sinopharm Shares to strengthen commercialization of Meimeixin® (米美欣®) and other products, leveraging Sinopharm's extensive distribution network across China to reach broader market coverage.

2Enhua Pharma (恩华药业)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-01
Description

Luye Pharma granted exclusive commercialization rights to Enhua Pharma for three long-acting injectable antipsychotic products in mainland China. The partnership leverages Enhua's established hospital and clinic network to expand market penetration across all levels of medical institutions and retail terminals.

luye.cn
3Shang Pharmaceutical Holdings (上药控股)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Shang Pharmaceutical Holdings as part of Bo'an Bioscience subsidiary's global biological product expansion strategy.

luye.cn
4Jianyou Pharma (健友股份)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Jianyou Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.

luye.cn
5Kexing Pharma (科兴制药)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Kexing Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.

luye.cn
6Bo'an Bioscience (博安生物)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bo'an Bioscience is a controlled subsidiary of Luye Pharma developing innovative biological drugs including BA1106 (anti-CD25 antibody for solid tumors), BA1302 (CD228 ADC), and other bispecific antibodies and cytokine fusion proteins in clinical development.

luye.cn
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Luye Pharma

Specialty Pharmaceuticalsluye.cn

Luye Pharma is a Hong Kong-listed specialty pharmaceutical company developing innovative drugs in oncology, CNS, and cardiovascular therapy using proprietary microsphere, liposome, and transdermal delivery platforms, with operations in 80+ countries and manufacturing across 8 global bases.

What Luye Pharma does

Luye Pharma Group (HKEX: 02186.HK) is a Hong Kong-listed specialty pharmaceutical company founded in 1994 and headquartered in Yantai, Shandong Province, with secondary operations in Shanghai. A subsidiary of Luye Life Sciences Group, it generates the substantial majority of its roughly RMB 6.3 billion (~$870M USD) FY2025 revenue from innovative and generic drugs across three therapeutic franchises — oncology (Baituowei goserelin microsphere, Zanbijia lurbinectedin), CNS (ERZOFRI paliperidone palmitate in the US, Rykindo risperidone microsphere, Ruoxinin for depression, rivastigmine and rotigotine transdermal patches), and cardiovascular/diabetes/ophthalmology — with an OTC health and wellness tail. Approximately 50 approved products are sold in over 80 countries through self-operated commercial teams in China and the US, supplemented by distribution partnerships with Sinopharm and Enhua Pharma in China and international commercialization partners in Europe, Japan, and Southeast Asia.

Luye Pharma firmographics

Firmographics
Name
Luye Pharma
Legal name
绿叶制药集团有限公司 (Luye Pharma Group Co., Ltd.)
Website
https://luye.cn
Company type
Public
Founded year
1994
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Luye Pharma is a Hong Kong-listed specialty pharmaceutical company developing innovative drugs in oncology, CNS, and cardiovascular therapy using proprietary microsphere, liposome, and transdermal delivery platforms, with operations in 80+ countries and manufacturing across 8 global bases.
Ownership category
akta.pro rank

Luye Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Innovative pharmaceutical drugs
  • Specialty oncology drugs
  • CNS therapeutics
  • Drug delivery platforms
  • Biologic drug development

Where Luye Pharma is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Luye Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sale of innovative drugs, generic drugs, and over-the-counter (OTC) health and wellness products across three segments: oncology, CNS (central nervous system), and cardiovascular. The company operates across 80+ countries including China, US, Europe, Japan, and emerging markets.
  2. New Product Commercialization: Revenue growth driven by commercialization of newly launched products including ERZOFRI® (paliperidone palmitate injectable suspension) in US, Rykindo® (risperidone long-acting microspheres), and other innovative drugs in China and global markets. New product revenue grew 56.8% year-over-year in 2025.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels1 record

Luye Pharma product offering

Product offering

Core offering

Luye Pharma is an international pharmaceutical company that researches, develops, manufactures, and commercializes innovative drugs across three core therapeutic areas: oncology, central nervous system (CNS) disorders, and cardiovascular diseases. The company operates advanced drug delivery technology platforms including microspheres, liposomes, and transdermal patches, and has a portfolio of approximately 50 approved products sold across 80+ countries through its 8 global manufacturing bases.

Product overview

Luye Pharma is an international pharmaceutical company dedicated to innovative drug R&D, manufacturing, and sales. The company focuses on three core therapeutic areas: anti-tumor chemotherapy drugs, central nervous system (CNS) innovative drugs, and biologics. Its advanced drug delivery technology platforms include microsphere, liposome, and transdermal delivery systems at international levels. The portfolio includes: CNS drugs such as ERZOFRI® (paliperidone palmitate monthly injection), Rykindo® (risperidone microsphere injection), and 若欣林® (for depression); oncology drugs including 百拓维® (goserelin microsphere) and 赞必佳® (lurbinectedin); biologic products like 博优景® (aflibercept) and 博优平® (dulaglutide); and transdermal patches including 利斯的明透皮贴剂 and 罗替高汀贴剂. The company has achieved 15 new product approvals across the US, China, Japan, and Europe between 2021-2025, with a robust pipeline including LY03015, LY03017, and LY03020 in CNS and various biologic candidates. Luye Pharma operates 8 global manufacturing bases and maintains an international GMP quality management system.

Differentiator

Problem solved

Functional benefit

Brands

  • Rykindo (瑞可盈): Risperidone extended-release microsphere injection - treatment for schizophrenia, launched in US
  • Erzofri (亿左福)
  • 若欣林 (Ruoxinin)
  • 百拓维 (Baituowei)
  • 赞必佳 (Zanbijia)
  • 博安生物 (Bo'an Biological)

Products and services

  • ERZOFRI® (paliperidone palmitate extended-release suspension injection) Monthly injectable for schizophrenia treatment; the only paliperidone palmitate monthly injection in the US offering a 'first month one injection' dosing regimen. Launched in the US in April 2025.
  • Rykindo® (risperidone extended-release microsphere injection) Long-acting injectable for schizophrenia treatment using microsphere drug delivery. Approved and launched in the United States.
  • 若欣林® Ruoxinin (tolafrazine sustained-release tablets) China's first self-developed Class 1 innovative chemical drug for depression treatment. Included in China's national medical insurance with rapid market penetration and received Level 1A recommendation as first-line treatment in the 2025 China Depression Prevention and Treatment Guidelines.
  • 百拓维® Baituowei (goserelin long-acting microsphere injection) The world's only currently marketed goserelin long-acting microsphere formulation for prostate cancer and breast cancer. Renewed in China's national medical insurance directory at the end of 2025 with multiplicative sales growth.

Quantifiable outcome

  • New product revenue grew 56.8% in 2025
  • +3 more outcomes

Companies that use Luye Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Luye Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Luye Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Sinopharm Group & Sinopharm Shares (国药控股、国药股份)coreChannel Partner/ Reseller/ Distributor · 1 March 2026Strategic collaboration with Sinopharm Group and Sinopharm Shares to strengthen commercialization of Meimeixin® (米美欣®) and other products, leveraging Sinopharm's extensive distribution network across China to reach broader market coverage.
  • Enhua Pharma (恩华药业)coreChannel Partner/ Reseller/ Distributor · 1 December 2025Luye Pharma granted exclusive commercialization rights to Enhua Pharma for three long-acting injectable antipsychotic products in mainland China. The partnership leverages Enhua's established hospital and clinic network to expand market penetration across all levels of medical institutions and retail terminals.
  • Shang Pharmaceutical Holdings (上药控股)majorChannel Partner/ Reseller/ DistributorPartnership with Shang Pharmaceutical Holdings as part of Bo'an Bioscience subsidiary's global biological product expansion strategy.
  • Jianyou Pharma (健友股份)majorChannel Partner/ Reseller/ DistributorPartnership with Jianyou Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.
  • Kexing Pharma (科兴制药)majorChannel Partner/ Reseller/ DistributorPartnership with Kexing Pharma as part of Bo'an Bioscience subsidiary's collaboration for global biological product expansion.
  • Bo'an Bioscience (博安生物)coreStrategic or Co-development PartnerBo'an Bioscience is a controlled subsidiary of Luye Pharma developing innovative biological drugs including BA1106 (anti-CD25 antibody for solid tumors), BA1302 (CD228 ADC), and other bispecific antibodies and cytokine fusion proteins in clinical development.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Luye Pharma competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Luye Pharma social profiles

Digital presence

Luye Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Luye Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Luye Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Luye Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Luye Pharma M&A and investment

M&A and investment

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luye Pharma

What does Luye Pharma do?

Luye Pharma is an international pharmaceutical company that researches, develops, manufactures, and commercializes innovative drugs across three core therapeutic areas: oncology, central nervous system (CNS) disorders, and cardiovascular diseases. The company operates advanced drug delivery technology platforms including microspheres, liposomes, and transdermal patches, and has a portfolio of approximately 50 approved products sold across 80+ countries through its 8 global manufacturing bases.

Is Luye Pharma a public or private company?

Luye Pharma is a public company. It is classified as public and is currently operating.

When was Luye Pharma founded?

Luye Pharma was founded in 1994. It employs 1,001 to 5,000 people.

Where is Luye Pharma based?

Luye Pharma is headquartered in Shanghai, China, in the Asia region.

How does Luye Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are new Product Commercialization.

Does Luye Pharma have an API?

No public API is recorded for Luye Pharma.

What industry is Luye Pharma in?

Luye Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLuye Pharma Gets FDA Clearance for LY03021 Depression Drug TrialsLuye Pharma received U.S. FDA clearance to begin clinical trials of LY03021 for major depressive disorder. The clearance was announced on November 17, 2026, via the Hong Kong Stock Exchange's regulatory disclosure system.BioSpaceStudy Published in The Journal of Clinical Psychiatry Shows Potential Benefit of Alternative Maintenance Dosing Strategies for Paliperidone Palmitate in Treatment of SchizophreniaA study published in The Journal of Clinical Psychiatry suggests that a 351 mg maintenance dose of paliperidone palmitate (ERZOFRI) may offer flexible dosing intervals for schizophrenia or schizoaffective disorder. The analysis showed that 351 mg every four weeks produced steady-state exposure comparable to 234 mg every three weeks, and 351 mg every six weeks matched 234 mg every four weeks. No clinical data currently supports these alternative regimens.EIN PresswireBlue Biotechnology Market to reach USD 12.08 Billion by 2035 at 7.15% CAGRThe global blue biotechnology market is projected to grow from USD 5.65 billion in 2024 to USD 12.08 billion by 2035, a 7.15% CAGR. North America holds about 45% of the market, with enzymes as the largest product segment and vaccine development the largest application. Growth is driven by genetic engineering advances and rising demand for sustainable solutions.PR NewswireTardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsightThe tardive dyskinesia market is projected to grow at an 8.1% CAGR from 2026 to 2036, reaching a 2025 size of USD 4.4 billion in the 7MM. The United States accounted for about 98% of that market, with approximately 1.7 million prevalent cases. Emerging therapies such as NBI-1065890 and SOM3355 are expected to reshape the market.PR NewswireTardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsightThe tardive dyskinesia market is projected to grow at an 8.1% CAGR from 2026 to 2036, reaching a 2025 size of USD 4.4 billion in the 7MM. The United States accounted for about 98% of that market, with approximately 1.7 million prevalent cases. Emerging therapies such as NBI-1065890 and SOM3355 are expected to reshape the landscape.AInvestLuye Pharma: stat sig results at 10 mg, 20 mg groups vs placeboLuye Pharma announced statistically significant results from its clinical trial LY03010 at 10 mg and 20 mg dosage groups compared to placebo, suggesting potential therapeutic advantages at higher doses. The study (NCT04922593) evaluated relative bioavailability against a listed drug, with the statistical significance indicating support for further regulatory review. The company cautions that early-stage findings do not guarantee regulatory approval or commercial success, and further analysis with larger trials may be necessary.AInvestLuye Pharma: new drug LY03015 achieved positive resultsLuye Pharma Group has initiated Phase I clinical trials in the U.S. and China for LY03015, a next-generation VMAT2 inhibitor being developed for Tardive Dyskinesia and Huntington's Disease. The randomized, double-blind, placebo-controlled study involves 120 healthy subjects evaluating safety, tolerability, and pharmacokinetics. The global VMAT2 inhibitor market for FDA-approved products reached approximately $1.659 billion in 2020, reflecting a 37.9% increase from 2019.Defense WorldLuye Pharma Group (LYPHF) Projected to Post Quarterly Earnings on MondayLuye Pharma Group is expected to release its quarterly earnings results before market opens on Monday, March 30th, with analysts projecting earnings of $0.0114 per share and revenue of $494.0430 million for the quarter. The stock is currently trading at $0.38 per share, with a 50-day moving average of $0.38 and a 200-day moving average of $0.34. The company is headquartered in Yantai, Shandong Province, China, and operates across three segments: innovative drugs, generic drugs, and over-the-counter health and wellness products.LinkedInVeterinary Diosmectite Market Tech-Driven Analysis | Trends & Consumer PatternsVerified Market Reports published a market analysis projecting the global Veterinary Diosmectite market to grow from USD 1.2 billion in 2024 to USD 2.5 billion by 2033, driven by rising animal gastrointestinal health awareness and AI integration. The report identifies key industry players including Luye Pharma Group, Ipsen, and Simcere, while highlighting regional growth opportunities across Asia Pacific, North America, and Europe. This analysis reflects broader trends in veterinary healthcare spending and the adoption of natural therapeutics for livestock and companion animals.Today on MedscapeOnce-Weekly Rotigotine Microspheres: A Better Option for PD?A phase 3 trial reported significant improvements in symptoms and quality of life for patients with early Parkinson's disease using a new formulation of rotigotine (LY03003) developed by Luye Pharma. The drug, administered via weekly intramuscular injections, demonstrated greater efficacy compared to a placebo, with nearly 30% higher responder rates. While currently approved only in China, research continues to explore its potential for approval in other markets.